Spinal Muscular Atrophy Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Awareness about Novel Therapies
   3. Market Restraints
      1. Limited Treatment Options
      2. Limited Awareness and Diagnosis
   4. Market Opportunities
      1. Increasing Effects of Gene Replacement Therapy
   5. Market Trends
      1. Increasing Adoption of Newborn Screening
      2. Expanding Pipeline of Therapeutic Candidates
5. MARKET SEGMENTATION
   1. By Drug
      1. Nusinersen
      2. Onasemnogene
      3. Abeparvovec
      4. Others
   2. By Type
      1. Werdnig-Hoffmann Disease
      2. Infant SMA
      3. Kugelberg-Welander Disease
      4. Adult SMA
   3. By Treatment
      1. Medication
      2. Physical Therapy
      3. Surgery
      4. Others
   4. By Route of Administration
      1. Intrathecal
      2. Intraspinal
      3. Subcutaneous
      4. Others
   5. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   6. By End User
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
   7. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AstraZeneca (U.K.)
      2. Abbott (U.S.)
      3. AbbVie Inc. (U.S.)
      4. Biogen (U.S.)
      5. Boehringer Ingelheim International GmbH. (Germany)
      6. Catalyst Pharmaceuticals, Inc.(U.S.)
      7. F. Hoffmann-La Roche Ltd. (Switzerland)
      8. GSK plc (U.K.)
      9. Ionis Pharmaceuticals, Inc. (U.S.)
      10. Leadiant Biosciences, Inc.(Italy)
      11. Novartis AG (Switzerland)
      12. Novo Nordisk A/S (Denmark)
      13. Pfizer Inc. (U.S.)
      14. PTC Therapeutics (U.S.)
      15. Regeneron Pharmaceuticals Inc (U.S.)
      16. Sanofi (France)
      17. Takeda Pharmaceutical Company Limited (Japan)
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Spinal Muscular Atrophymarket?

The global market of Spinal Muscular Atrophy is projected to reach USD 6,321.38 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Spinal Muscular Atrophymarket?

The global Spinal Muscular Atrophy market has an estimated annual growth rate of 13.3% .

Q.3. What are the recent trends of Spinal Muscular Atrophymarket?

Increasing adoption of newborn screening and expanding pipeline of therapeutic candidates are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Spinal Muscular Atrophy?

The major companies profiled in this report include AstraZeneca (U.K.), Abbott (U.S.), AbbVie Inc. (U.S.), Biogen (U.S.), Boehringer Ingelheim International GmbH. (Germany), Catalyst Pharmaceuticals, Inc.(U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), GSK plc (U.K.), Ionis Pharmaceuticals, Inc. (U.S.), Leadiant Biosciences, Inc.(Italy), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), PTC Therapeutics (U.S.), Regeneron Pharmaceuticals Inc (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan)., among others.

Q.5. Which region is estimated to held highest CAGR inSpinal Muscular Atrophymarket?

North America is estimated to hold biggest share in the market for Spinal Muscular Atrophy.